Yao-Yao Zhang

Severe cutaneous adverse reaction to aumolertinib plus vebreltinib in an EGFR-mutant NSCLC patient: a case report

The combination of aumolertinib and vebreltinib has emerged as an effective therapeutic strategy for advanced non-small cell lung cancer(NSCLC) harboring EGFR mutations with concurrent MET amplification. However, the safety profile of this combination regimen remains incompletely characterized, particularly with re...